 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- Kadcyla (ado-trastuzumab emtansine) / Roche
Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_654;
Conclusions The study findings suggested that T-DM1 is effective in managing HER2-positive metastatic breast cancer and the outcomes with T-DM1 biosimilar usage in the real world are consistent with the published evidence of randomized controlled clinical trials with T-DM1. So, this biosimilar can be a reasonable option in routine clinical practice in India.
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Ujvira (trastuzumab emtansine biosimilar) / Zydus Cadila
Clinical, PK/PD data, Journal: Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India. (Pubmed Central) - Jun 4, 2022
Results demonstrated biosimilarity between UJVIRA and Kadcyla in terms of efficacy, safety, pharmacokinetics, and immunogenicity. Therefore, UJVIRA could prove to be a cost-effective treatment alternative for HER2-positive metastatic breast cancer patients in India.